Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Endometrial cancer.
- F. Amant, P. Moerman, P. Neven, D. Timmerman, E. van Limbergen, I. Vergote
- Medicine
- Lancet
- 2005
Each year, endometrial cancer develops in about 142,000 women worldwide, and an estimated 42,000 women die from this cancer. The typical age-incidence curve for endometrial cancer shows that most… Expand
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
- I. Vergote, C. Tropé, +15 authors N. Reed
- Medicine
- The New England journal of medicine
- 2 September 2010
BACKGROUND
Primary debulking surgery before initiation of chemotherapy has been the standard of care for patients with advanced ovarian cancer.
METHODS
We randomly assigned patients with stage IIIC… Expand
Endometrial cancer
- F. Amant, P. Moerman, P. Neven, D. Timmerman, I. Vergote
- Medicine
- The Lancet
- 12 August 2005
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.
- N. Colombo, C. Creutzberg, +8 authors C. Sessa
- Medicine
- Annals of oncology : official journal of the…
- 2 December 2015
The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on… Expand
Patient-derived xenograft models: an emerging platform for translational cancer research.
- M. Hidalgo, F. Amant, +11 authors A. Villanueva
- Medicine, Biology
- Cancer discovery
- 9 January 2014
UNLABELLED
Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the… Expand
Clinical management of uterine sarcomas.
- F. Amant, A. Coosemans, M. Debiec-Rychter, D. Timmerman, I. Vergote
- Medicine
- The Lancet. Oncology
- 1 December 2009
Malignant pure mesenchymal uterine tumours encompass endometrial stromal sarcoma (ESS), uterine leiomyosarcoma, and undifferentiated sarcomas. This Review discusses pathology, preoperative diagnosis,… Expand
Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning.
- S. Deprez, F. Amant, +8 authors S. Sunaert
- Medicine
- Journal of clinical oncology : official journal…
- 20 January 2012
PURPOSE
To uncover the neural substrate of cognitive impairment related to adjuvant chemotherapy, we studied cerebral white matter (WM) integrity before and after chemotherapy by using magnetic… Expand
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
- N. Colombo, C. Creutzberg, +8 authors C. Sessa
- Medicine
- International Journal of Gynecologic Cancer
- 12 November 2015
Abstract The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference… Expand
HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
- T. Van Gorp, I. Cadron, +6 authors I. Vergote
- Medicine
- British Journal of Cancer
- 8 February 2011
Background:Recently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human epididymis secretory protein 4 (HE4) and CA125 successfully classified patients as presenting a high or low risk for… Expand
Chemotherapy‐induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients
- S. Deprez, F. Amant, +10 authors S. Sunaert
- Psychology, Medicine
- Human brain mapping
- 1 March 2011
A subgroup of patients with breast cancer suffers from mild cognitive impairment after chemotherapy. To uncover the neural substrate of these mental complaints, we examined cerebral white matter (WM)… Expand